ATS 2025: Real-world cohort study aligns with GSK depemokimab narrative
GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better outcomes.
GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better outcomes.
What's Your Reaction?
